Bioreactor Lab Equipment

Our Pipeline

Treatments for Tomorrow

Combined approaches designed to achieve profound immune system regeneration and prevention of immune system aging.

US Patent

Issued for TRIIM Treatment

5 Programs

Ready for Clinical Development

Revenue

Personalized treatment & testing

Longevity Biotech

Clinical Development Pipeline

Developing GH biobetter to enable thymus regeneration treatment adoption at scale

Category
Candidate / Application
Pre-clinical
Phase 1
Phase 2
Phase 3
Biosimilars for Thymus Regeneration
Somatropin (TRIIM-X)
Somatropin Biobetter
2 Undisclosed Candidates
Biologics for Induced Immune Tolerance
Islet Cell Transplants (T1D)
Organ Transplant Grafts (Heart)
Undisclosed Biologics Platform
Small Molecule & Target Discovery
Target Discovery - Functional Genomics
Target Discovery - Epigenetic Pathways
1 Undisclosed Oral Candidate
Active Development
Undisclosed Programs

Thymus Regeneration

Our lead program, TRIIM-X, has demonstrated thymus regeneration and epigenetic age reversal in human clinical trials. We're developing next-generation biobetters to enable broader adoption.

Immune Tolerance

Novel biologics designed to induce immune tolerance for transplantation applications, including islet cell transplants for Type 1 Diabetes and organ transplant graft acceptance.

Target Discovery

Leveraging functional genomics and epigenetic pathway analysis to identify novel small molecule targets for immune system rejuvenation and aging intervention.

Partner With Us

Interested in our pipeline programs or partnership opportunities? Contact our team to learn more.

Contact Us Participate in Trials